Molecular Partners reaches all milestones in Centocor deal

Milestone

Molecular Partners AG, which is pioneering the development of DARPins, a novel class of therapeutic proteins, has announced that it has reached all milestones of the research phase of its collaboration with Centorcor earlier than anticipated, successfully selecting and characterising DARPin antagonists to multiple targets.

The collaboration began in January 2008. “We are very pleased with the rapid progress of this collaboration”, said Christian Zahnd, CEO of Molecular Partners. “This is a significant step forward in our strategy to strengthen our proprietary pipeline with selected partnered compounds.”